Advanced Oncotherapy PLC’s (AVO) Speculative Buy Rating Reaffirmed at Beaufort Securities
Advanced Oncotherapy PLC (LON:AVO)‘s stock had its “speculative buy” rating reaffirmed by investment analysts at Beaufort Securities in a research report issued on Monday.
Shares of Advanced Oncotherapy PLC (LON:AVO) opened at 102.66 on Monday. Advanced Oncotherapy PLC has a 12 month low of GBX 98.00 and a 12 month high of GBX 217.25. The company has a 50 day moving average of GBX 114.22 and a 200 day moving average of GBX 142.00. The stock’s market cap is GBX 58.24 million.
About Advanced Oncotherapy PLC
Advanced Oncotherapy Plc is a United Kingdom-based company. The Company is engaged in providing medical technology for cancer treatment and managing a health-related property. The Company operates in three business segments: Proton Therapy, Single Dose Intra-Operative Radiotherapy Treatment (SDIORT) and Healthcare related properties.
Receive News & Ratings for Advanced Oncotherapy PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy PLC and related companies with MarketBeat.com's FREE daily email newsletter.